Innovita released its 2026 half-year report. First-half operating revenue was 141 million yuan, down 49.1% year on year. Net profit attributable to the parent was 31.12 million yuan, down 75.1% year on year. Net profit attributable to the parent after deducting non-recurring items was 19.64 million yuan, down 82.3% year on year. Net operating cash flow was negative 62.38 million yuan, down 173.0% year on year. Earnings per share were 0.2271 yuan. In the second quarter, operating revenue was 31.92 million yuan, down 54.1% year on year. Net profit attributable to the parent was a loss of 9.52 million yuan, down 132.0% year on year. Net profit attributable to the parent after deducting non-recurring items was a loss of 15.61 million yuan, down 168.7% year on year. As of the end of the second quarter, total assets were 2.127 billion yuan, down 6.5% from the end of the previous year. Net assets attributable to the parent were 2.029 billion yuan, down 1.1% from the end of the previous year. The company said the decline in performance was mainly affected by changes in the intensity of respiratory disease epidemics and intensifying competition in the in vitro diagnostics market. It plans to increase investment in new products and new businesses, and has already obtained registration certificates for a combined antigen test kit for metapneumovirus and parainfluenza virus, as well as approval for a glial fibrillary acidic protein assay kit.
Innovita Biological Technology Co. Ltd. AFirst-half net profit fell 75.1% and revenue dropped 49.1% due to lower respiratory disease testing demand and competition.
